Encore Medical, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-09-15. It has amended it 7 times. As of its latest filing, on 2026-08-10, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have applied for listing of our common stock on the NYSE American Market (NYSE American) under the symbol “EMI” and the closing of this offering is contingent on such listing.From the S-1/A filed 2026-08-10
Shares offered
This includes [3,000,000] shares that we are selling in this offering, which may be resold in the public market immediately, and the issuance of 1,000,000 shares of common stock for the License Agreement which is contingent on the completion of this offering, which will be unregistered.From the S-1/A filed 2026-08-10
Use of proceeds
We intend to use the net proceeds from this offering primarily to fund our clinical trials, particularly for stroke and migraine indications.From the S-1/A filed 2026-08-10
Net loss or income
We had a net loss of $928,088 for the year ended December 31, 2025, and a net loss of $278,915 for the three months ended March 31, 2026.From the S-1/A filed 2026-07-15
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-09-15 | Registration statement filed | S-1 |
| 2025-12-30 | Registration statement amended | S-1/A |
| 2026-03-03 | Registration statement amended | S-1/A |
| 2026-03-24 | Registration statement amended | S-1/A |
| 2026-04-06 | Registration statement amended | S-1/A |
| 2026-07-01 | Registration statement amended | S-1/A |
| 2026-07-15 | Registration statement amended | S-1/A |
| 2026-08-10 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for Encore Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.